---
title: "HSBC Research's Investment Ratings and Target Prices for Pharmaceutical and Biotechnology Stocks (Table)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259748360.md"
description: "HSBC Research has released its latest investment ratings and target prices for pharmaceutical and biotechnology stocks. The main stocks and their ratings include: BeiGene (Buy, target price USD 375), Innovent Biologics (Buy, target price HKD 115), Kelun-Biotech (Buy, target price HKD 549), China National Pharmaceutical Group (Buy, target price HKD 9.6), CSPC Pharma (Buy, target price HKD 10.5), Hengrui Pharma (Buy, target price RMB 79), Fosun Pharma (Hold, target price HKD 26.5), LIVZON PHARMA (Hold, target price HKD 37.23), HANSOH PHARMA (Buy, target price HKD 47)"
datetime: "2025-10-02T07:07:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259748360.md)
  - [en](https://longbridge.com/en/news/259748360.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259748360.md)
generator: "portal-rs"
---

# HSBC Research's Investment Ratings and Target Prices for Pharmaceutical and Biotechnology Stocks (Table)

HSBC Research published a research report, listing the latest investment ratings and target prices for pharmaceutical and biotechnology stocks as follows:

Stock | Investment Rating | Target Price

BeiGene (ONC.US) | Buy | USD 323 -> USD 375

Innovent Biologics (01801.HK) | Buy | HKD 110 -> HKD 115

Kintor Pharmaceutical (06990.HK) | Buy | HKD 354 -> HKD 549

China National Pharmaceutical Group (01177.HK) | Buy | HKD 8.49 -> HKD 9.6

CSPC Pharma (01093.HK) | Buy | HKD 10.7 -> HKD 10.5

Hengrui Pharma (600276.SH) | Buy | RMB 73 -> RMB 79

Fosun Pharma (02196.HK) | Hold | HKD 17.2 -> HKD 26.5

LIVZON PHARMA (01513.HK) | Hold | HKD 37.54 -> HKD 37.23

HANSOH PHARMA (03692.HK) | Buy | HKD 47

### Related Stocks

- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [Livzon MABPharm wins China approval for Lecankitug psoriasis injection](https://longbridge.com/en/news/297167246.md)
- [HANSOH PHARMA  1H26 Net Profit Up 35.8% YoY to RMB4.258B; Interim DPS Hiked 23% to HKD0.285](https://longbridge.com/en/news/297019908.md)
- [CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer](https://longbridge.com/en/news/297024431.md)
- [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md)
- [Hansoh Pharmaceutical cuts convertible bond conversion price to HK$56.54 per share](https://longbridge.com/en/news/297047890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**